The European Consortium on Continuous Pharmaceutical Manufacturing (ECCPM), looks at issues surrounding continuous processing
In the last years, the FDA has endorsed the transition towards continuous manufacturing (CM) as a way to shorten the supply chain, increase agility and flexibility of development and manufacturing and to improve product quality through real time process control. Significant resources and capital investment are required by industry, according to CDER director Janet Woodcock.